Vanguard Personalized Indexing Management LLC Has $978,000 Stock Position in Quest Diagnostics Incorporated (NYSE:DGX)

Vanguard Personalized Indexing Management LLC reduced its position in Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 6.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 8,026 shares of the medical research company’s stock after selling 556 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Quest Diagnostics were worth $978,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Yousif Capital Management LLC lifted its position in Quest Diagnostics by 5.3% during the second quarter. Yousif Capital Management LLC now owns 26,926 shares of the medical research company’s stock worth $3,785,000 after acquiring an additional 1,359 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Quest Diagnostics during the third quarter worth approximately $493,000. LPL Financial LLC lifted its position in Quest Diagnostics by 4.4% during the second quarter. LPL Financial LLC now owns 50,252 shares of the medical research company’s stock worth $7,063,000 after acquiring an additional 2,103 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Quest Diagnostics by 1.3% during the third quarter. Massmutual Trust Co. FSB ADV now owns 16,439 shares of the medical research company’s stock worth $2,003,000 after acquiring an additional 218 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Quest Diagnostics by 5.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 29,395 shares of the medical research company’s stock worth $4,132,000 after acquiring an additional 1,421 shares during the last quarter. 87.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DGX has been the subject of a number of analyst reports. Barclays initiated coverage on shares of Quest Diagnostics in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $145.00 price target for the company. UBS Group lifted their price target on shares of Quest Diagnostics from $135.00 to $137.00 and gave the company a “neutral” rating in a research report on Thursday, December 7th. Citigroup lifted their price target on shares of Quest Diagnostics from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, December 11th. TheStreet downgraded shares of Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Quest Diagnostics from $148.00 to $149.00 and gave the company a “neutral” rating in a research report on Friday, November 17th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $146.91.

Get Our Latest Stock Analysis on Quest Diagnostics

Quest Diagnostics Stock Performance

Shares of NYSE:DGX opened at $130.01 on Tuesday. The company’s 50 day simple moving average is $134.16 and its 200 day simple moving average is $131.42. The stock has a market capitalization of $14.62 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 2.73 and a beta of 0.92. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.31 and a quick ratio of 1.20. Quest Diagnostics Incorporated has a 1 year low of $119.59 and a 1 year high of $148.91.

Quest Diagnostics (NYSE:DGXGet Free Report) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.04. The firm had revenue of $2.29 billion for the quarter, compared to analysts’ expectations of $2.25 billion. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.98 earnings per share. As a group, research analysts predict that Quest Diagnostics Incorporated will post 8.78 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 22nd. Shareholders of record on Monday, April 8th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date of this dividend is Friday, April 5th. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.71. Quest Diagnostics’s payout ratio is presently 37.92%.

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.